mFOLFOX6: Clinical Trials

20 trials of mFOLFOX6, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown, 5 recruiting, 4 completed, 2 not yet recruiting. 20 Phase 3, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 320Unknown 7, Recruiting 5, Completed 4, Not yet recruiting 2, Terminated 1, Withdrawn 1
Phase 26Unknown 3, Completed 2, Not yet recruiting 1

Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer
Phase 3RecruitingGenmab9602026-08-112026-11-03
SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC
Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer
Phase 3RecruitingSixth Affiliated Hospital, Sun Yat-sen University2042026-05-202026-07-01
A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)
Cetuxima-β, Envafolimab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC)
Phase 2 / Phase 3Not yet recruitingSun Yat-sen University5902025-06-012025-05-06
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 - Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum
Phase 3RecruitingJun Huang1662025-01-182025-12-24
Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD)
mFOLFOXIRI, mFOLFOX6 - Colorectal Cancer
Phase 3Not yet recruitingYanhong Deng3402022-10-092022-10-07
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC
TRS003, China-approved Bevacizumab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC)
Phase 3UnknownZhejiang Teruisi Pharmaceutical Inc.1262022-08-012022-05-18
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Bemarituzumab, mFOLFOX6, Placebo - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 3CompletedAmgen5472022-03-072026-10-23
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
mFOLFOX6, mFOLFOXIRI, FOLFIRI - Colorectal Cancer
Phase 3RecruitingDominik Paul Modest5072021-12-062025-12-12
Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC
Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer
Phase 2 / Phase 3UnknownRuijin Hospital2002021-11-012021-04-30
The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer
resection of primary tumor, XELOX, mFOLFOX6 - Metastatic Colon Cancer, Surgery
Phase 3UnknownFudan University6272020-04-012020-06-04
CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
mFOLFOX6 - Patients With Resected Stage II Colon Cancer
Phase 3RecruitingCentre Hospitalier Universitaire Dijon19802020-01-172026-07-10
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
Varlitinib, mFOLFOX6, Placebo - Gastric Cancer
Phase 2 / Phase 3CompletedASLAN Pharmaceuticals522017-08-312022-02-15
IV Ascorbic Acid in Advanced Gastric Cancer
ascorbic acid, mFOLFOX6 - Gastric Cancer
Phase 3UnknownSun Yat-sen University2002017-03-122017-05-18
Cetuximab Monotherapy Maintenance Treatment in mCRC
Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer
Phase 2 / Phase 3UnknownRuijin Hospital5002016-11-012016-11-30
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
mFOLFOX6, FOLFIRI, Pembrolizumab - Colorectal Carcinoma
Phase 3CompletedMerck Sharp & Dohme LLC3072015-11-302024-10-03
Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis
Raltitrexed-based chemotherapy, 5-fluorouracil-based chemotherapy - Colorectal Cancer, Liver Metastasis
Phase 3TerminatedZhejiang University3602015-10-112020-07-14
Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients
mFOLFOX6, XELOX, Placebo ChangTai Keli - Colon Cancer
Phase 2 / Phase 3UnknownNanjing NingQi Medicine Science and Technology Co., Ltd.3602015-06-012015-08-03
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases
Oxaliplatin HAI, Oxaliplatin IV, mFOLFOX6 - Colorectal Cancer
Phase 2 / Phase 3CompletedGustave Roussy, Cancer Campus, Grand Paris1042015-05-262024-10-28
A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis
mFOLFOX6, HAI - Metastatic Colorectal Cancer
Phase 3UnknownYuhong Li1422014-03-012024-03-04
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab
bevacizumab [Avastin], cetuximab, mFOLFOX6 - Colorectal Cancer
Phase 3WithdrawnHoffmann-La Roche2011-06-012016-11-02

Conditions studied

Colorectal Neoplasms (12)  ·  Stomach Neoplasms (3)  ·  Colonic Neoplasms (2)  ·  Neoplasm, Residual (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Rectal Neoplasms (1)

Sponsors

Ruijin Hospital (2)  ·  Sun Yat-sen University (2)  ·  ASLAN Pharmaceuticals (1)  ·  Amgen (1)  ·  Centre Hospitalier Universitaire Dijon (1)  ·  Dominik Paul Modest (1)  ·  Fudan University (1)  ·  Genmab (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  Hoffmann-La Roche (1)  ·  Jun Huang (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Nanjing NingQi Medicine Science and Technology Co., Ltd. (1)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (1)  ·  Yanhong Deng (1)

Countries

China (9)  ·  France (3)  ·  Australia (2)  ·  Estonia (2)  ·  Lithuania (2)  ·  Malaysia (2)  ·  Singapore (2)  ·  South Korea (2)  ·  Taiwan (2)  ·  Thailand (2)  ·  United States (2)  ·  Argentina (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Bulgaria (1)

Top investigators

Ding Ke-Feng, PHD/MD (1)  ·  Dominik Modest, Prof. Dr. (1)  ·  Jun Huang, MD (1)  ·  Jun Huang, PhD (1)  ·  Jun Zhang, MD & Ph.D (1)  ·  Rui-hua Xu, MD.,PhD. (1)  ·  Xiaoning Wang, Professor (1)  ·  Yanhong Deng, Ph.D. (1)  ·  Yifeng Wang, MD (1)  ·  Yu-hong Li, MD, Ph D (1)

Results publications

PMID 30081865, PMID 33264544, PMID 33812497, PMID 35366831, PMID 35427471, PMID 36369901, PMID 38308771, PMID 40341124

NIH funding

2014 (1), 2015 (1), 2023 (1)